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Heinrich Heimann, MD, FRCOphth bAbstractProton beam radiotherapy of uveal melanoma can be administered as primary treatment, as salvage therapy for recurrent tumor,
and as neoadjuvant therapy prior to surgical resection. The physical properties of proton beams make it possible to deliver high-
doses of radiation to the tumor with relative sparing of adjacent tissues. This form of therapy is effective for a wider range of uveal
melanoma than any other modality, providing exceptionally-high rates of local tumor control. This is particularly the case with dif-
fuse iris melanomas, many of which are unresectable. The chances of survival, ocular conservation, visual preservation and avoid-
ance of iatrogenic morbidity depend greatly on the tumor size, location and extent. When treating any side-effects and/or
complications, it is helpful to consider whether these are the result of collateral damage or persistence of the irradiated tumor
(‘toxic tumor syndrome’).
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The aims of proton beam radiotherapy of uveal melanoma
are to eradicate any threat of metastatic disease while con-
serving the eye with as much useful vision as possible.
As with other ionizing radiation, protons damage cells by
disrupting DNA so that tumor cells lose their reproductive
ability, hence entering senescence or undergoing apoptosis.1
Tissue damage is greatest at the point where the protons
stop moving so that there is a ‘Bragg Peak’ of ionization, with
relative sparing of healthy tissues both proximal and distal to
the tumor target. Furthermore, the beam can be highly colli-
mated, thereby reducing collateral damage to adjacent struc-
tures such as the optic nerve and fovea.The aims of this review are to discuss the Liverpool ap-
proach to proton beam radiotherapy.2–4 This is done in the
context of the current literature on the subject.5,6Methods
Initial assessment
Initial investigations are aimed at determining the suitabil-
ity of the patient for proton beam radiotherapy, estimating
the likely outcomes, and planning treatment. The benefits
and risks of all the therapeutic options are discussed.7 The tu-
mor size and location are defined by slit-lamp examinatione:
al.com
nia, San
152 B. Damato et al.and/or ophthalmoscopy as well as by color photography and
ultrasonography. Secondary effects of the tumor on the eye,
such as retinal detachment, are identified in addition to any
unrelated, concurrent ocular disease. The axial length of
the eye is measured to enable a computerized, 3D model
of the eye to be generated. This is done using the EyePlan
system developed at Clatterbridge.Insertion of tantalum markers
If the tumor involves the choroid and/or ciliary body, then
tantalum markers are inserted and these range from three
to five in number, depending on the tumor shape and
whether or not the optic disk can be used as the ‘fourth
marker’ (Fig. 1). Unlike other authors, who perform a 360
peritomy and who use muscle slings, we prefer to perform
only a sectorial peritomy, involving only a third or half of
the eye. With small, post-equatorial tumors, the overlying
rectus muscle is temporarily dis-inserted to improve expo-
sure and enhance accuracy. Before dividing any rectus mus-
cles, the suture knot-to-limbus distances are measured and
recorded; these measurements help to re-insert the
muscle(s) more precisely by ensuring that the original
knot-to-limbus distances are retained. The tumor margins
are defined by transillumination and/or indentation. When
performing transillumination, care is taken not to be misled
by any penumbra, which can occur with transpupillary trans-
illumination if the tumor is thick; in such cases, trans-ocular
transillumination is superior. The first author (BD) has
developed a right-angled 20-gauge transilluminator for this
purpose. Marker-tumor, marker-marker and marker-limbus
measurements are taken for each marker. For small, poster-
ior tumors, Damato has devised a transilluminator that
shines light through the eyes of the marker, which are visi-
ble with binocular indirect ophthalmoscopy (Altomed Ltd,
Tyne and Wear, UK) (Fig. 2).Figure 1. Drawing showing tantalum markers sutured to the sclera. The
distances from the tumor margins, the limbus and from each other are
measured. (From B. Damato, Ocular Tumours: Diagnosis and Treatment,
Butterworth Heineman, 2000).With iris melanomas and small ciliary body tumors with vis-
ible extension into the anterior chamber, the treatment can
be administered safely without the use of tantalum markers.Simulation
A 3D computer model of the eye is generated according
to ocular biometry, tumor ultrasonography, color photogra-
phy, intra-operative marker measurements as well as radio-
graphs showing the marker positions (Fig. 3). As
mentioned, with tumors involving iris, which are visible exter-
nally, markers are not required (Fig. 4). The model also shows
the proton beam, the eyelids and the optic nerve. The direc-
tion of gaze is adjusted so as to minimize collateral damage
to lens, optic nerve and fovea.Treatment
A total dose of 53 to 70 Gy is administered in four, daily frac-
tions. Some centers hyper-fractionate the treatment in the hope
of reducing damage to healthy tissues. The patient’s head is
held in a frame, with a personalized face-mask and dental bite
to ensure immobility. The position of the eye is maintained by
means of a strategically-located visual target. Correct position-
ing of the eye is checked by radiography and by observing the
eye with a closed-circuit TV during administration of the radio-
therapy. The eyelids are retracted out of the field of the radia-
tion beam. In Liverpool, if it is not possible for the upper eyelid
to be pulled entirely out of the radiation field, the treatment is
administered through the closed eyelid, with the patient gaz-
ing at the fixation target with the fellow eye.
With choroidal tumors, the proton beam radiotherapy is
administered with safety margins of 2.0–2.5 mm. To prevent
collateral damage to the optic nerve and fovea, these mar-
gins can be reduced with small, juxtapapillary and juxtafoveal
tumors if the patient is highly cooperative and if the measure-
ments are known to be accurate. Ciliary body melanomas
tend to develop diffuse spread circumferentially, which can
be extensive if the tumor is large. Wider safety margins of
up to 4 mm may therefore be used, in such cases.
With iris melanomas, we administer circumferential safety
margins of 3 mm or one clock hour, whichever is greater, and
with posterior safety margins extending 2 mm posterior to
limbus if the tumor does not involve angle or 4 mm posterior
to limbus if it does. If the iris tumor shows diffuse growth or
seeding, then radiotherapy is delivered to the entire anterior
segment with the beam extending posteriorly to ora serrata.Figure 2. Transilluminator for localizing posterior tantalum markers,
designed by the first author (BD).
Figure 3. Proton beam treatment plan for a juxtapapillary choroidal melanoma in the left eye. The tumor had basal dimensions of 7.5 mm by 6.6 mm with
a thickness of 0.9 mm. Three tantalum markers were inserted, using the optic disk as the ‘fourth marker’ (a). Proton beam diagram superimposed on a
fundus photograph. Note the notch in the beam, designed to avoid collateral damage to the optic nerve (b). Three-dimensional diagram showing tumor,
nerve, markers and beam (c). Vertical slice through eye showing minimal irradiation of the optic nerve (d).
Figure 4. Infero-nasal iris melanoma in the left eye of a 74-year-old woman. The tumor had basal dimensions of 4.4 mm by 2.2 mm with a thickness of
1.6 mm. Proton beam plan superimposed on the anterior-segment photograph (a). Horizontal section of the eye showing the penetration of the beam to
the level of the ora (b).
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Biopsy greatly enhances estimation of the survival proba-
bility by allowing the Tumor, Node and Metasis (TNM) Stage
to be integrated with genetic and histologic data. Damato
and associates have developed an online program for pro-
ducing a personalized prognosis, also taking the patient’s
age and gender into account.8 This biopsy is performed after
completion of the radiotherapy so as to avoid any risk of tu-
mor seeding, and is done trans-retinally for choroidal tumors
and trans-sclerally for ciliary body tumors.Long-term care
After completion of the radiotherapy, the patient is mon-
itored for any complications or side-effects. Long-term sur-
veillance also includes screening for metastatic disease,
either in selected patients having a poor prognosis or all pa-
tients. We prefer to screen selectively, according to survival
estimates using an online program he has developed with
associates in clinical engineering and pathology. This uses
clinical, histologic and genetic data, also taking the patient’s
age and gender into account. Our preferred method is
154 B. Damato et al.abdominal magnetic resonance imaging, performed every six
or 12 months, according to the risk of metastasis.9Counseling
Counseling of patients and close relatives forms an essen-
tial part of care. At the initial visit, patients are informed of
their condition, the natural history of uveal melanoma and
the prognosis in terms of survival and ocular outcomes. The
therapeutic options are discussed so that they can choose
the optimal treatment for their particular condition and per-
sonality while considering their personal needs and fears.
During the treatment, they are kept abreast of what is hap-
pening and what they might expect from day to day. After
the proton beam treatment is completed, they are counseled
repeatedly on their survival probability and on any ocular
symptoms that might arise. Any stress or depression is man-
aged, with the help of a health psychologist or specialist
nurse. Feedback is obtained constantly so that any care can
be personalized appropriately.Results
Most centers administer proton beam radiotherapy simi-
larly so that the outcomes are likely to be the same. Any dif-
ferences in the results are likely to occur because of variations
in patient selection and in the management of side-effects
and complications. This article therefore focuses on our case
series, which comprises 349 patients with choroidal mela-
noma, 88 patients receiving sectorial radiotherapy for iris
melanoma and 12 patients undergoing proton beam radio-
therapy of the entire anterior segment.2–4Figure 5. Ocular outcomes of proton beam radiotherapy of choroidal melan
according to tumor height (b). Preservation of vision of 20/40 according to pos
(d). (From Damato et al., Proton beam radiotherapy of choroidal melanoma: T
Oncology Biology Physics, Volume 62, Issue 5, 1 August 2005, Pages 1405–1Local tumor control
Posterior segment tumors
The cumulative risk of local treatment failure at 5 years is
low (i.e. 1–6%) (Fig. 5a).2 The strongest predictor of local recur-
rence is large tumor size. Larger tumors are more likely to show
high-grade (i.e., aggressive) malignancy and to have sub-clin-
ical, diffuse spread. In some cases, local recurrence can be
treated by repeating the radiotherapy or by performing local
resection or transpupillary thermotherapy. Survival after re-
irradiation is no worse than after secondary enucleation.10
Iris melanomas
The 5-year incidence of local tumor recurrence is approx-
imately 6% (95% Confidence Interval, 0–14%).3 Marginal tu-
mor recurrence can develop after sectorial proton beam
treatment if the extent of a diffuse melanoma is underesti-
mated. Central tumor recurrences can occur but are rare,
possibly arising if a narrow Bragg peak does not coincide
with the tumor depth (unpublished cases). Such recurrent tu-
mor can be treated by repeating the proton beam radiother-
apy or by enucleation.
Vision
Posterior segment melanomas
The chances of conserving vision of 20/40, 20/200 and
Count Fingers are approximately 32%, 42% and 73% at 8 years
respectively (Fig. 5b and c).2 The most important factors pre-
dicting visual loss are large tumor size, retinal invasion, ciliary
body involvement, posterior tumor extension and reduced ini-
tial visual acuity. If the visual loss results from direct collateral
damage to the disk or macula, then it is untreatable.11 Visualoma. Local tumor control (a). Conservation of vision of 20/200 or better
terior tumor extension (c). Ocular conservation according to tumor height
he Liverpool-Clatterbridge experience, International Journal of Radiation
411).
Proton beam radiotherapy of uveal melanoma 155loss caused by macular edema or retinal detachment may be
managed by anti-angiogenic agents, intraocular steroid injec-
tions or implants and/or phototherapy or resection of the irra-
diated tumor.1 Any pre-treatment retinal detachment or
edema involving the fovea can be treated by transpupillary
thermotherapy or photodynamic therapy, delivered to the tu-
mor immediately after completion of the radiotherapy.12Iris melanomas
Most the eyes retain the pre-treatment visual acuity unless
complications such as cataract or keratopathy develop
(Fig. 6).3 Treatable causes of visual loss include cataract and
hyphema. Cataract and keratopathy are treated in the usual
manner. Recurrent hyphema may cease after photodynamic
therapy of the irradiated tumor.13Ocular conservation
Posterior segment melanomas
The risk of enucleation is approximately 5.4–14% at
5 years (Fig. 5d).2,14 The most common reasons for enucle-
ation are neovascular glaucoma and local tumor recurrence.
Risk factors include ciliary body involvement, posterior tumor
extension close to disc, large tumor size and retinal invasion.
Some authors advocate prophylactic anti-angiogenic agents
as a means of preventing neovascular complications. The
enucleation can be performed in the usual manner, using sur-
geon’s preferred orbital implant.Iris melanomas
The usual reason for secondary enucleation after proton
beam radiotherapy of iris melanoma is local tumor recur-
rence.3 Another reason is painful keratopathy caused by lim-
bal stem-cell deficiency if this does not respond to
conservative measures. Neovascular glaucoma is rare.Figure 6. Visual acuity before proton beam radiotherapy of iris mela-
noma and at the latest known status. Each circle represents one case, and
each line passing through this circle indicates an additional case.
A = amblyopia; B = bullous keratopathy; C = cataract; G = glaucoma;
H = hyphema; R = recurrence. (From Damato et al. Proton beam radio-
therapy of iris melanoma, International Journal of Radiation Oncology
Biology Physics, Volume 63, Issue 1, 1 September 2005, Pages 109–115).Miscellaneous ocular outcomes
Posterior-segment melanomas
Irradiation of the eyelid causes an acute burn, which
leaves a de-pigmented scar, with loss of lashes and squa-
mous metaplasia of the tarsal conjunctiva with keratinization
if the lid margin is affected. Such keratinization can cause
pain and keratopathy if it occurs in the upper eyelid. It is
managed by showing the patient how to debride the tarsus,
removing the keratin with a cotton bud. Since 1993, we
have prevented this complication by administering the pro-
ton beam radiotherapy through the closed eye if it is not
possible to retract the eyelid entirely out of the radiation
field. When the medial canthus is included in the beam,
there may be canaliculitis, which results in intractable epiph-
ora. Irradiation of the lacrimal gland can cause atrophy of
this gland, with keratoconjunctivitis sicca. Other external
eye complications include stem-cell deficiency in some pa-
tients receiving extensive limbal irradiation, an unstable tear
film, and telangiectasia of the episcleral blood vessels. Sub-
conjunctival markers can erode through irradiated conjunc-
tiva to result in an indolent ulcer that is difficult to treat.
This complication can be prevented by placing each marker
outside the radiation field, or as far from the limbus as pos-
sible, or by removing the marker before it erodes through
the conjunctiva.
Collateral damage to healthy intraocular tissues can cause
cataract, retinal and choroidal vasculopathy involving the fo-
vea, and optic neuropathy. Irradiated tumor tissue can be-
come ischemic and/or exudative, resulting in macular
edema, serous retinal detachment, retinal ischemia, rubeosis
iridis and neovascular glaucoma. ‘Toxic Tumor Syndrome’.
The stimulus to neovascularization is enhanced by capillary
closure in irradiated retina, optic neuropathy and detached
retina, which becomes ischemic because of its separation
from the choriocapillaris. The toxic tumor syndrome is man-
aged by intraocular steroids or anti-angiogenic agents or
by treatment of the irradiated tumor with phototherapy or
resection.12,15 Rubeosis can also regress after intra-cameral
or intravitreal injection of anti-angiogenic agents.16 Some
authors have reported successful prevention of neovascular
glaucoma by hyper-fractionation and/or delivering smaller
doses of radiation to iris and ciliary body.17 Such results
would indicate that neovascular complications can be the re-
sult of collateral damage to healthy tissues, at least in some
patients.
If the tumor has perforated the retina, there can be recur-
rent vitreous hemorrhage. This can be treated by transpupil-
lary thermotherapy or photodynamic therapy if there is a
clear view after spontaneous resolution or vitrectomy. If these
measures fail, then endoresection of the irradiated tumor
may be considered.
Tumor biopsy can cause vitreous hemorrhage and, rarely,
seeding of melanoma cells to other parts of the globe sub-
conjunctivally. For these reasons, we prefer to perform this
intervention after completion of the radiotherapy.Iris melanomas
Cataract is common, especially if the tumor is extensive or
if lens opacities are present before treatment. Glaucoma
tends to occur as a result of annular tumor spread around
the angle or by pigment scatter from a necrotic tumor. Such
156 B. Damato et al.ocular hypertension can be managed with a drainage im-
plant, since the tumor is sterile.18,19 Limbal stem-cell defi-
ciency develops in approximately 30% of patients
undergoing total anterior segment irradiation. Rarely, recur-
rent hyphema can arise from the telangiectatic tumor vessels,
which can be treated by photodynamic therapy.13
Survival
Posterior segment melanomas
The risk factors for metastatic death are the same as for
other forms of treatment and include large basal tumor diam-
eter, thick tumor and extraocular tumor extension.2 If biopsy
is performed, then epithelioid melanoma cytomorphology,
chromosome 3 loss and class 2 gene expression profile would
indicate an increased risk of metastasis.8 Local tumor recur-
rence is associated with increased mortality20; however,
whether the recurrence causes the metastatic disease or
whether it is merely an indicator of increased tumor malig-
nancy is not known.
Iris melanomas
Data on survival after proton beam radiotherapy of iris
melanomas are scanty. The general literature suggests that
the most important factors predicting metastatic disease
are diffuse tumor growth, secondary glaucoma (which corre-
lates closely with diffuse growth), and large tumor size.21
Discussion
Indications
Of all therapeutic modalities, proton beam radiotherapy
has the widest inclusion criteria. The placement of tantalum
markers requires less surgical precision than plaque insertion,
with both methods requiring accurate measurements for
treatment planning. For these reasons, some centers rely
exclusively on proton beam radiotherapy as a means of con-
serving the eye and vision. Only a few centers around the
world have, however, have facilities for proton beam radio-
therapy for ocular tumors.
The proton beam radiotherapy can be administered as pri-
mary treatment or as salvage therapy for local tumor recur-
rence after plaque radiotherapy, phototherapy or surgical
resection. Some centers advocate neoadjuvant proton beam
radiotherapy before endoresection as a means of preventing
tumor seeding and metastasis.22 However, such radiotherapy
frequently causes significant ocular morbidity and there is no
evidence to show that it is indeed beneficial.
Even when plaque radiotherapy of uveal melanoma is pos-
sible, proton beam radiotherapy may be preferable when it re-
duces the chances of local tumor recurrence and/or collateral
damage to the optic disk and/or fovea because the tumor
has an awkward size, shape and/or location. With iris tumors,
proton beam radiotherapy has more favorable dosimetry than
brachytherapy and does not require any surgery.
Contraindications
If collateral damage to the optic disk is likely because the tu-
mor extends within a disk diameter of the optic disk margin,
then endoresection may be preferred if conservation of visionis highly desirable (e.g., in a monocular patient), if the patient
accepts the controversial nature of such surgery, if the opera-
tion is unlikely to damage the fovea because of a medial tumor
location, and if the surgeon is experienced in the technique.23
Concerns about tumor dissemination seem exaggerated.24
If the proton beam radiotherapy is likely to cause trouble-
some epiphora or if the toxic tumor syndrome is likely be-
cause the tumor is bulky or associated with an extensive
retinal detachment, then trans-scleral tumor resection may
be considered if the surgeon is experienced in the technique
and if the patient is fit for hypotensive anesthesia.15
Retinopathy is more likely to develop in diabetic patients,
who may need more intensive treatment for macular edema
and other complications. As with other forms of conservative
therapy, the patient must be sufficiently motivated to under-
go what may be a prolonged course of treatment and follow-
up; otherwise, enucleation may be more appropriate.
Conclusions
Proton beam radiotherapy of uveal melanoma achieves
high rates of local tumor control and it is therefore likely that
any influence on survival is similar to that of enucleation. Collat-
eral damage to healthy ocular structures is predictable and
eminently treatable in the case of cataract. The toxic tumor
syndrome is less predictable but often treatable by a variety
of methods. Any iatrogenic morbidity is more likely to be trea-
ted effectively if the pathology is better understood. As with
any form of therapy, it is important to treat not only the tumor
but the patient, addressing all needs and concerns by appro-
priate counseling and other psychological measures.
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